<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460346</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101180</ELocationID><Abstract><AbstractText>COVID-19 vaccines have reduced the negative health and economic impact of the COVID-19 pandemic by preventing severe disease, hospitalizations and deaths. In the new socio-economic normality, the COVID-19 vaccination strategy can be universal or high-risk and seasonal or not seasonal, and different vaccines can be used. The universal vaccination strategy can achieve greater health and herd immunity effects and is associated with greater costs than the high-risk vaccination strategy. In each country, the optimal COVID-19 vaccination strategy must be decided by considering the advantages and disadvantages and assessing the costs, health effects and cost-effectiveness of the universal and high-risk vaccination strategies. The universal vaccination strategy should be implemented when the objective of the vaccination program is to achieve the greatest health benefits from COVID-19 vaccination and when its incremental cost-effectiveness ratio is lower than EUR 30,000-50,000 per QALY or LYG. The use of adapted vaccines targeting currently circulating variants of SARS-CoV-2 is necessary to avoid the immune escape of emerging variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plans-Rubió</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4424-2971</Identifier><AffiliationInfo><Affiliation>College of Physicians of Barcelona, 08017 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination strategies</Keyword><Keyword MajorTopicYN="N">adapted COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">herd immunity</Keyword><Keyword MajorTopicYN="N">high-risk vaccination</Keyword><Keyword MajorTopicYN="N">seasonal vaccination</Keyword><Keyword MajorTopicYN="N">universal vaccination</Keyword></KeywordList><CoiStatement>The author declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460346</ArticleId><ArticleId IdType="pmc">PMC11511555</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101180</ArticleId><ArticleId IdType="pii">vaccines12101180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO)  WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. 2020.  [(accessed on 8 September 2024)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>Singh P., Anand A., Rana S., Kumar A., Goel P., Kumar S., Gouda K.C., Singh H. Impact of COVID-19 vaccination: A global perspective. Front. Public Health. 2024;11:1272961. doi: 10.3389/fpubh.2023.1272961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1272961</ArticleId><ArticleId IdType="pmc">PMC10808156</ArticleId><ArticleId IdType="pubmed">38274537</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Statement on the Fifteenth Meeting of the IHR Emergency Committee on the COVID-19 Pandemic. 2023.  [(accessed on 8 September 2024)].  Available online:  https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.</Citation></Reference><Reference><Citation>Our World in Data  Coronavirus (COVID-19) Vaccinations.  [(accessed on 8 September 2024)].  Available online:  https://ourworldindata.org/covid-vaccinations.</Citation></Reference><Reference><Citation>Menegale F., Manica M., Zardini A., Guzzetta G., Marziano V., d’Andrea V., Trentini F., Ajelli M., Poletti P., Merler S. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw. Open. 2023;6:e2310650. doi: 10.1001/jamanetworkopen.2023.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10650</ArticleId><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  The Transition from the Acute Phase of COVID-19. WHO/EURO:2023-7637-47404-69640. 2023.  [(accessed on 8 September 2024)].  Available online:  https://iris.who.int/bitstream/handle/10665/369063/WHO-EURO-2023-7637-47404-69640-eng.pdf?sequence=1.</Citation></Reference><Reference><Citation>Plans-Rubió P. Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2. Vaccines. 2023;11:1836. doi: 10.3390/vaccines11121836.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121836</ArticleId><ArticleId IdType="pmc">PMC10747774</ArticleId><ArticleId IdType="pubmed">38140240</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)  Seasonal Influenza Vaccination Recommendations and Coverage Rates in EU/EEA Member States—An Overview of Vaccination Recommendations for 2020–21 and Coverage Rats for the 2019 to 2020–21 Influenza Seasons. ECDC: Stockholm, Sweden.  [(accessed on 9 October 2024)];2023  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/Seasonal-flu-vacc-recs-coverage-rates-EU-EEA.pdf.</Citation></Reference><Reference><Citation>Regan J.J., Moulia D.L., Link-Gelles R., Godfrey M., Mak J., Najdowski M., Rosenblum H.G., Shah M.M., Twentyman E., Meyer S., et al. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥ 6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1140–1146. doi: 10.15585/mmwr.mm7242e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7242e1</ArticleId><ArticleId IdType="pmc">PMC10602621</ArticleId><ArticleId IdType="pubmed">37856366</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Age Care, Australian Government  COVID-19 Vaccine Advice and Recommendations for 2024.  [(accessed on 10 September 2024)]; Available online:  https://www.health.gov.au/our-work/covid-19-vaccines/getting-your-vaccination.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)  Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU/EEA.  [(accessed on 10 September 2024)];2023  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-strategies-march-2023.pdf.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Underlying Conditions and the Higher Risk for Severe COVID-19.  [(accessed on 9 September 2024)]; Available online:  https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.</Citation></Reference><Reference><Citation>Ajufo E., Rao S., Navar A.M., Pandey A., Ayers C.R., Khera A. US population at increased risk of severe illness from COVID-19. Am J. Prev. Cardiol. 2021;6:100156. doi: 10.1016/j.ajpc.2021.100156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpc.2021.100156</ArticleId><ArticleId IdType="pmc">PMC7880833</ArticleId><ArticleId IdType="pubmed">33615285</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe S.A., Choe Y.J., Miyairi I. Universal versus risk-based strategies for vaccinating children against COVID-19: Japan and Korea. BMJ Paediatr. Open. 2024;8:e002391. doi: 10.1136/bmjpo-2023-002391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjpo-2023-002391</ArticleId><ArticleId IdType="pmc">PMC11002420</ArticleId><ArticleId IdType="pubmed">38575171</ArticleId></ArticleIdList></Reference><Reference><Citation>Plans-Rubió P. Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2. Vaccines. 2022;8:736. doi: 10.3390/vaccines10050736.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050736</ArticleId><ArticleId IdType="pmc">PMC9144560</ArticleId><ArticleId IdType="pubmed">35632492</ArticleId></ArticleIdList></Reference><Reference><Citation>Plans Rubió P. Aplicación del Análisis Coste/Efectividad de los Medicamentos y Programas de Salud en la Planificación Sanitaria (Application of the Cost-Effectiveness of Medicines and Health Programs in the Health Planning) Elsevier; Amsterdam, The Netherlands: 2014.</Citation></Reference><Reference><Citation>McCabe C., Claxton K., Culyer A.J. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics. 2008;26:733–744. doi: 10.2165/00019053-200826090-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200826090-00004</ArticleId><ArticleId IdType="pubmed">18767894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Gum D., Merlin T. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed? Value Health. 2018;21:938–943. doi: 10.1016/j.jval.2018.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2018.01.017</ArticleId><ArticleId IdType="pubmed">30098671</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosser L., Hutton D.W., Gebremariam A., Rose A., Nyamuswa C., Janusz C., Pike J., Wallace C., Ortega-Sanchez I., University of Michigan. COVID-19 Vaccination Modeling Team. Economic analysis of COVID-19 vaccination Economic Analysis of COVID-19 Vaccination.  (Advisory Committee on Immunization Practices (ACIP) Meeting COVID-19 Vaccines, Atlanta, GA; June 27, 2024). [(accessed on 9 September 2024)]; Available online:  https://www.atsdr.cdc.gov/sites/peer_review/docs/tox-profile-for-nickel-fdprc-508.pdf.</Citation></Reference><Reference><Citation>Krammer F., Ellebedy A.H. Variant-adapted COVID-19 booster vaccines. Science. 2023;382:157–159. doi: 10.1126/science.adh2712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adh2712</ArticleId><ArticleId IdType="pubmed">37824671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Huang Z., Xiao J., Wu Y., Xia N., Yuan Q. Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness. Viruses. 2024;16:184. doi: 10.3390/v16020184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020184</ArticleId><ArticleId IdType="pmc">PMC10893260</ArticleId><ArticleId IdType="pubmed">38399960</ArticleId></ArticleIdList></Reference><Reference><Citation>Girl P., von Buttlar H., Mantel E., Antwerpen M.H., Wölfel R., Müller K. Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2. Vaccines. 2024;12:515. doi: 10.3390/vaccines12050515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12050515</ArticleId><ArticleId IdType="pmc">PMC11126034</ArticleId><ArticleId IdType="pubmed">38793766</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute for Health Metrics and Evaluation (IHME)   COVID-19 Vaccine Efficacy Summary. IHME, University of Washington; Seattle, WA, USA: 2023.  [(accessed on 7 September 2024)].  Available online:  https://www.healthdata.org/research-analysis/diseases-injuries/covid/covid-19-vaccine-efficacy-summary.</Citation></Reference><Reference><Citation>World Health Organization (WHO)  Tracking SARS-CoV-2 Variants.  [(accessed on 7 September 2024)].  Available online:  https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>World Health Organization (WHO)  Statement on the Antigen Composition of COVID-19 Vaccines.  [(accessed on 8 September 2024)].  Available online:  https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines.</Citation></Reference><Reference><Citation>World Health Organization (WHO)  COVID-19 Vaccines with WHO Emergency Use Listing.  [(accessed on 17 September 2024)].  Available online:  https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA)  COVID-19 Medicines. Authorized COVID-19 Vaccines.  [(accessed on 17 September 2024)]; Available online:  https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines.</Citation></Reference><Reference><Citation>Food and Drug Administration (FDA)  COVID-19 Vaccines for 2024–2025.  [(accessed on 17 September 2024)]; Available online:  https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2024-2025.</Citation></Reference><Reference><Citation>Pilapitiya D., Wheatley A.K., Tan H.X. Mucosal vaccines for SARS-CoV-2: Triumph of hope over experience. EBioMedicine. 2023;92:104585. doi: 10.1016/j.ebiom.2023.104585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104585</ArticleId><ArticleId IdType="pmc">PMC10154910</ArticleId><ArticleId IdType="pubmed">37146404</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . COVID-19 Vaccine Tracker and Landscape. World Health Organization; Geneva, Switzerland: 2020.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Sterlin D., Mathian A., Miyara M., Mohr A., Anna F., Claër L., Quentric P., Fadlallah J., Devilliers H., Ghillani P., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021;13:eabd2223. doi: 10.1126/scitranslmed.abd2223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>